{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:34:40Z","timestamp":1779323680485,"version":"3.51.4"},"reference-count":15,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2008,2,7]],"date-time":"2008-02-07T00:00:00Z","timestamp":1202342400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2008,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>The most frequent nervous system complications of multiple myeloma are peripheral neuropathy and epidural spinal cord compression. Myelomatous meningitis (MM) has been considered rare. The current study was performed to characterize the clinical presentation, treatment, and outcome of MM.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>The study was a case series of 14 patients with cerebrospinal fluid (CSF)\u2010positive MM who were treated at a tertiary care university medical center.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Fourteen patients with advanced multiple myeloma were treated with involved\u2010field radiotherapy (to the brain in 5 patients and the spine in 6 patients) and intra\u2010CSF chemotherapy (ventricular in 10 patients and lumbar in 4 patients). The best response to treatment included 6 partial responses and 8 patients with progressive disease. The median duration of response was 2.5 months (range, 0\u20136 months). Cause of death was progressive neurologic disease in 6 patients, combined systemic and neurologic disease in 6 patients, and systemic disease progression in 2 patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>MM is rare and morbid entity (6\u2010month neurologic disease progression\u2010free survival rate of 7%), and appears to be no more responsive to treatment than solid tumor carcinomatous meningitis. Cancer 2008. \u00a9 2008 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.23330","type":"journal-article","created":{"date-parts":[[2008,2,7]],"date-time":"2008-02-07T11:51:54Z","timestamp":1202385114000},"page":"1562-1567","source":"Crossref","is-referenced-by-count":33,"title":["Myelomatous meningitis"],"prefix":"10.1002","volume":"112","author":[{"given":"Marc C.","family":"Chamberlain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Glantz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,3,19]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.61.9.1423"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-001-0387-6"},{"key":"e_1_2_5_4_2","first-page":"680","article-title":"Leptomeningeal myeloma","volume":"103","author":"Slager UE","year":"1979","journal-title":"Arch Pathol Lab Med."},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.140.2.256"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19921001)70:7<1899::AID-CNCR2820700716>3.0.CO;2-3"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1994.tb00198.x"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1159\/000333918"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199912)62:4<228::AID-AJH5>3.0.CO;2-3"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.3.561"},{"key":"e_1_2_5_11_2","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1200\/JCO.1987.5.10.1655","article-title":"A prospective randomized trial of single\u2010agent versus combination chemotherapy in meningeal carcinomatosis","volume":"5","author":"Hitchens R","year":"1987","journal-title":"J Clin Oncol."},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.10.3110"},{"key":"e_1_2_5_13_2","first-page":"3394","article-title":"A randomized trial comparing intrathecal sustained\u2010release ara\u2010C (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors","volume":"11","author":"Glantz M","year":"1999","journal-title":"Clin Cancer Res."},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2004.08.012"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.7311"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.23330","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.23330","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T09:50:28Z","timestamp":1760262628000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.23330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,19]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["10.1002\/cncr.23330"],"URL":"https:\/\/doi.org\/10.1002\/cncr.23330","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3,19]]}}}